The HIV-1 envelope glycoprotein: structure, function and interactions with neutralizing antibodies.

Area of Science:

• Immunology
• Virology
• Vaccinology

Background:

• The AIDS pandemic necessitates an effective vaccine to prevent new human immunodeficiency virus type 1 (HIV-1) infections.
• Broadly neutralizing antibodies (bNAbs) are crucial for blocking HIV-1 entry by targeting the viral envelope glycoprotein.
• HIV-1's envelope glycoprotein employs mechanisms like sequence variation and glycan shielding to evade antibody responses.

Purpose of the Study:

• To review the landscape of broadly neutralizing human antibodies against HIV-1.
• To discuss the targets, characteristics, and limitations of current bNAb isolation and elicitation strategies.
• To highlight advancements in structure-guided immunogen design for vaccine development.

Main Methods:

• Review of scientific literature on HIV-1 broadly neutralizing antibodies.
• Analysis of antibody epitope clusters on the HIV-1 envelope glycoprotein.
• Examination of structure-guided immunogen design strategies.

Main Results:

• Numerous bNAbs have been isolated, targeting diverse epitope clusters covering the HIV-1 envelope glycoprotein surface.
• These bNAbs exhibit varied potency, mechanisms of action, and binding kinetics.
• Current immunization strategies have not yet elicited bNAb responses.

Conclusions:

• Despite challenges posed by HIV-1's defenses, bNAbs offer therapeutic and preventive potential.
• Structure-guided immunogen design shows promise for eliciting bNAbs by engaging germline antibody precursors.
• Further research in immunogen design is critical for advancing HIV-1 vaccine development.